医学
国际民航组织
支架
狭窄
冠状动脉疾病
外科
放射科
耐火材料(行星科学)
冲程(发动机)
内科学
基因
化学
工程类
天体生物学
物理
机械工程
生物化学
作者
Nangorgo Coulibaly,Griffin Ernst,Hussain Shallwani,Beau M. Hawkins,Usman Baber,Hakeem J Shakir
标识
DOI:10.1136/bmjsit-2022-000171
摘要
Objectives This report describes the use of an Everolimus-eluting stent (Xience Skypoint stent) for the treatment of medically-refractory ICAD. Design Retrospective, case-series Setting In-hospital patients Participants All patients in this report had a history of stroke secondary to ICAD. All patients failed aggressive medical treatments and had recurrence of symptoms despite anticoagulation or dual-antiplatelet therapy plus a statin. Diagnostic angiogram in each case showed severe vessel stenosis, therefore patients were recommended for intracranial artery stenting. Main outcome measures Technical feasibility of deploying Xience Skypoint stent for treatmet of ICAD. Results The Xience Skypoint stent was safely and effectively deployed in the vertebral artery (x1) and the internal carotid artery (x2) using trans-ulnar (x1), trans-radial (x1), and trans-femoral (x1) approaches without the use of an intermediate catheter. Conclusion Second-generation EES such as Xience Skypoint may be utilized for treatment of medically-refractory ICAD. This technical report serves as a proof of concept for further studies analysing long-term safety and efficacy of such stents for treatment of ICAD.
科研通智能强力驱动
Strongly Powered by AbleSci AI